Top Story

Recombinant Factor VIII product increased inhibitor development risk

October 24, 2014

One recombinant Factor VIII product was associated with an increased risk for inhibitor formation compared with similar products for the treatment of severe hemophilia A, according to study results.

Thierry Calvez, MD, MSc, of Sorbonne University and Institut Pierre Louis d'Epidémiologie et de Santé Publique in Paris, and colleagues sought to confirm the results of the Research of Determinants of Inhibitor Development (RODIN) study. Results of this analysis indicated Kogenate FS (Bayer Healthcare), a second-generation full-length recombinant Factor VIII product, increased the risk for inhibitor formation in previously untreated patients with severe hemophilia A.

In the Journals

Tumor characteristics influenced impact of adjuvant radiotherapy in prostate cancer

October 23, 2014
Tumor characteristics considerably influenced the impact of adjuvant radiotherapy on survival outcomes in patients with node-positive prostate cancer, according to study…
figure Health Care Legislative and Regulatory Update

Reducing the burden of Medicare's physician quality-reporting system

October 23, 2014
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of…

Morale rises, but more physicians feel overextended

October 23, 2014
An increasing number of physicians reported they are overextended or at full capacity, according to results of a national survey conducted this year of more than 20,000…
More News Headlines »

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video

Nomogram predicted recurrence risk among women who underwent APBI

September 26, 2014
Jessica Wobb, MD, senior resident in radiation oncology at Beaumont Health System in Birmingham, Mich., describes how…
More »

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »